These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 13705073)

  • 1. Electroencephalographic study of children immunized against measles with live attenuated virus vaccine.
    GIBBS FA; GIBBS EL; ROSENTHAL IM
    N Engl J Med; 1961 Apr; 264():800-1. PubMed ID: 13705073
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines.
    Brandler S; Tangy F
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):271-91. PubMed ID: 17869338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
    Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
    Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Measurement of the in vitro immune response of live attenuated measles virus vaccine and antibody levels in 0 to 10-year-old children].
    Unalan H; Ustaçelebi S
    Mikrobiyol Bul; 1985 Oct; 19(4):218-28. PubMed ID: 3831724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Electroencephalographic and clinical observations in active measles vaccination with attenuated live vaccine].
    Müller K; Eckoldt G
    Dtsch Gesundheitsw; 1966 Jan; 21(2):70-6. PubMed ID: 5940860
    [No Abstract]   [Full Text] [Related]  

  • 6. Replication-incompetent adenoviruses as vectors for protective immunization against measles virus infection.
    Schindler C; Fooks A; Stephenson J; Liebert UG
    Behring Inst Mitt; 1994 Dec; (95):109-15. PubMed ID: 7755504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revaccination against measles--a pilot study.
    Watson GI; Nichols JA; Robshaw JR
    J R Coll Gen Pract; 1975 Dec; 25(161):863-73. PubMed ID: 1223275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China.
    Dai B; Chen ZH; Liu QC; Wu T; Guo CY; Wang XZ; Fang HH; Xiang YZ
    Bull World Health Organ; 1991; 69(4):415-23. PubMed ID: 1934235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical measles in children previously immunized with attenuated measles virus vaccines.
    Cherry JD; Feigin RD; Lobes LA; Shackelford PG
    Pediatrics; 1972 Nov; 50(5):712-7. PubMed ID: 5084185
    [No Abstract]   [Full Text] [Related]  

  • 11. [Epidemiological investigations on measles in unvaccinated and vaccinated children (author's transl)].
    Wiedermann G; Ambrosch F
    Wien Klin Wochenschr; 1976 Sep; 88(17):545-54. PubMed ID: 997537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on immunity to measles. II. Prophylactic and serological studies on the use of live and attenuated measles-virus vaccine].
    Egami T
    Kumamoto Igakkai Zasshi; 1966 May; 40(5):539-62. PubMed ID: 4164172
    [No Abstract]   [Full Text] [Related]  

  • 13. Exaggerated natural measles following attenuated virus immunization.
    St Geme JW; George BL; Bush BM
    Pediatrics; 1976 Jan; 57(1):148-9. PubMed ID: 1246490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
    Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
    Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunity to and incidence of measles in a population of Parisian children].
    Gendrel D; Chemillier-Truong M; Rodrigue D; Bosco O; Specker I; Raymond J; Saliou P; Lebon P
    Arch Fr Pediatr; 1992 Dec; 49(10):865-8. PubMed ID: 1304151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector.
    Kovarik J; Gaillard M; Martinez X; Bozzotti P; Lambert PH; Wild TF; Siegrist CA
    Virology; 2001 Jun; 285(1):12-20. PubMed ID: 11414801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal age for vaccinating Nigerian children against measles. II. Seroconversion to measles vaccine in different age groups.
    Ogunmekan DA; Harry TO
    Trop Geogr Med; 1981 Dec; 33(4):379-82. PubMed ID: 7342385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cytostatic therapy reduces the immune defense. Children treated for leukemia have impaired immunity against measles and rubella].
    Nilsson A; Nordin M; De Milito A; Grillner L; Chiodi F; Björk O
    Lakartidningen; 2000 Nov; 97(45):5116-8. PubMed ID: 11116890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccination against measles with Schwarz vaccine. Clinical, serologic and electroencephalographic results in 50 children].
    Fourrier A; Beaussart M; Camier P; Lacombe A
    Lille Med; 1968 Oct; 13(8):848-63. PubMed ID: 5743597
    [No Abstract]   [Full Text] [Related]  

  • 20. Lack of efficacy of the standard potency Edmonston-Zagreb live, attenuated measles vaccine in African infants.
    Kiepiela P; Coovadia HM; Loening WE; Coward P; Botha G; Hugo J; Becker PJ
    Bull World Health Organ; 1991; 69(2):221-7. PubMed ID: 1860150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.